Conformation-X Therapeutics
Conformation-X Therapeutics is an immune-oncology company developing biologic and orally available small-molecule therapeutics that target immune checkpoints and the tumor microenvironment. The company reports conducting ex vivo and in vivo preclinical proof-of-concept studies for lead programs and has completed a funding round to support pipeline advancement.
Industries
Nr. of Employees
small (1-50)
Conformation-X Therapeutics
Canton, Massachusetts, United States, North America
Products
Preclinical program targeting HHLA2
A preclinical therapeutic program targeting the HHLA2 immune checkpoint with reported ex vivo and in vivo proof-of-concept data.
Preclinical program targeting IL18BP
A preclinical therapeutic program addressing IL18BP with reported ex vivo and in vivo proof-of-concept data.
IL18BP program
A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, part of their innovative immune-oncology pipeline.
HHLA2 program
A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, targeting immune checkpoints in cancer therapy.
Preclinical program targeting HHLA2
A preclinical therapeutic program targeting the HHLA2 immune checkpoint with reported ex vivo and in vivo proof-of-concept data.
Preclinical program targeting IL18BP
A preclinical therapeutic program addressing IL18BP with reported ex vivo and in vivo proof-of-concept data.
IL18BP program
A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, part of their innovative immune-oncology pipeline.
HHLA2 program
A lead asset of Conformation-X Therapeutics with successful ex vivo and in vivo proof-of-concept studies, targeting immune checkpoints in cancer therapy.
Expertise Areas
- Immune-oncology
- Tumor microenvironment therapeutics
- Small-molecule immune checkpoint inhibitors
- Biologic therapeutic development
Key Technologies
- Biologic therapeutics
- Oral small-molecule drug development
- In vivo preclinical models
- Ex vivo functional assays
News & Updates
Announcement of an oversubscribed funding tranche of $3.65M, bringing total raised to over $13.5M, and disclosure of successful ex vivo and in vivo proof-of-concept studies for HHLA2 and IL18BP programs.
Closed an oversubscribed funding tranche of $3.65M, bringing total capital raised since inception to over $13.5M.
Announcement of an oversubscribed funding tranche of $3.65M, bringing total raised to over $13.5M, and disclosure of successful ex vivo and in vivo proof-of-concept studies for HHLA2 and IL18BP programs.
Closed an oversubscribed funding tranche of $3.65M, bringing total capital raised since inception to over $13.5M.